- Featured Product
- KD/KO Validated
Vimentin Polyklonaler Antikörper
Vimentin Polyklonal Antikörper für WB, IHC, IF-P, ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human, Maus, Ratte
Anwendung
WB, IHC, IF-P, ELISA
Konjugation
Unkonjugiert
Kat-Nr. : 22031-1-AP
Synonyme
Geprüfte Anwendungen
Erfolgreiche Detektion in WB | HEK-293-Zellen, A549-Zellen, HeLa-Zellen, Mausherzgewebe |
Erfolgreiche Detektion in IHC | humanes Ovarialkarzinomgewebe, humanes Tonsillitisgewebe Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen. |
Erfolgreiche Detektion in IF-P | humanes Nierengewebe |
Empfohlene Verdünnung
Anwendung | Verdünnung |
---|---|
Western Blot (WB) | WB : 1:500-1:2000 |
Immunhistochemie (IHC) | IHC : 1:50-1:500 |
Immunfluoreszenz (IF)-P | IF-P : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, check data in validation data gallery |
Veröffentlichte Anwendungen
WB | See 18 publications below |
IHC | See 4 publications below |
IF | See 8 publications below |
Produktinformation
22031-1-AP bindet in WB, IHC, IF-P, ELISA Vimentin und zeigt Reaktivität mit human, Maus, Ratten
Getestete Reaktivität | human, Maus, Ratte |
In Publikationen genannte Reaktivität | human, Maus, Ratte |
Wirt / Isotyp | Kaninchen / IgG |
Klonalität | Polyklonal |
Typ | Antikörper |
Immunogen | Vimentin fusion protein Ag16898 |
Vollständiger Name | vimentin |
Berechnetes Molekulargewicht | 466 aa, 54 kDa |
Beobachtetes Molekulargewicht | 57 kDa |
GenBank-Zugangsnummer | BC000163 |
Gene symbol | VIM |
Gene ID (NCBI) | 7431 |
Konjugation | Unkonjugiert |
Form | Liquid |
Reinigungsmethode | Antigen-Affinitätsreinigung |
Lagerungspuffer | PBS with 0.02% sodium azide and 50% glycerol |
Lagerungsbedingungen | Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
Vimentin, also named as VIM, belongs to the intermediate filament family. Vimentin is class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. Vimentin is important for stabilizing the architecture of the cytoplasm. Monocyte-derived macrophages secrete vimentin into the extracellular space in vitro. Secretion of vimentin was enhanced by the proinflammatory cytokine tumor necrosis factor-alpha (TNFA; 191160) and inhibited by the antiinflammatory cytokine IL10 (124092), suggesting that vimentin is involved in the immune response. Vimentin has specialized functions that contribute to specific dynamic cellular processes. As a phosphoprotein, 55-60 kDa of vimentin proteins can be observed due to the different phosphorylation level. Isoforms of vimentin (49 kDa and 60 kDa) had also been reported. (PMID: 8640945, 22728585).
Protokolle
PRODUKTSPEZIFISCHE PROTOKOLLE | |
---|---|
WB protocol for Vimentin antibody 22031-1-AP | Protokoll herunterladen |
IHC protocol for Vimentin antibody 22031-1-AP | Protokoll herunterladenl |
IF protocol for Vimentin antibody 22031-1-AP | Protokoll herunterladen |
STANDARD-PROTOKOLLE | |
---|---|
Klicken Sie hier, um unsere Standardprotokolle anzuzeigen |
Publikationen
Species | Application | Title |
---|---|---|
Cell Death Dis ZNF652 exerts a tumor suppressor role in lung cancer by transcriptionally downregulating cyclin D3 | ||
J Transl Med Single-cell and spatial transcriptome profiling reveal CTHRC1+ fibroblasts promote EMT through WNT5A signaling in colorectal cancer | ||
Tissue Eng Part C Methods Pretreatment with Inflammatory Factors Altered the Secretome of Human Amniotic Epithelial Cells | ||
Clin Respir J SIRT3 Inhibits Cell Proliferation of Nonsmall Cell Lung Carcinoma by Inducing ROS Production | ||
Biochim Biophys Acta Mol Basis Dis A novel Cdc42-YAP-fibronectin signaling axis regulates ameloblast differentiation during early enamel formation | ||
Breast Cancer Res SMYD4 promotes MYH9 ubiquitination through lysine monomethylation modification to inhibit breast cancer progression |